Skip to main content

Advertisement

Table 1 Characteristics of patients with NVG

From: Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

  Injection Group Control Group P
Total Patients 21 22  
Gender    0.45
 Male 10 13  
 Female 11 9  
Age 60.1 ± 13.8 (32–81) 58.6 ± 17.3 (28–81) 0.76
Diagnosis    0.90
 CRVO 8 7  
 BRVO 2 2  
 DR 11 13  
Baseline IOP (mm Hg) 46.4 ± 13.3 (24.5–76.0) 45.0 ± 14.9 (23.5–78.5) 0.74
Prior intravitreal injection 0 0  
NVI/NVA Degree    0.90
 NVI only 3 2  
 NVI&NVA (Open-angle) 5 4  
 NVI&NVA (partial Closed-angle) 2 3  
 NVI&NVA (Closed-angle) 11 13  
PRP before    0.55
 none 12 9  
 Incomplete 6 8  
 complete 3 5  
BCVA (LogMAR) 1.1 ± 0.4 (0.3–1.6) 1.2 ± 0.4 (0.4–1.6) 0.65
Pre-medications 2.5 ± 0.5 (2–3) 2.6 ± 0.5 (2–3) 0.66
  1. Note: The difference in gender was compared between the two groups using the chi-square test, the difference in NVI/NVA degree was compared using two-tailed Fisher’s exact test, and the differences in diagnosis and PRP before were compared using the corrected chi-square test. Differences in age, IOP, BCVA and anti-glaucoma medications were compared using the t test